HIV Drug Resistance in Cambodian Patients
Author Information
Author(s): Nouhin Janin, Ngin Sopheak, Ken Sreymom, Ouk Vara, Segeral Olivier, Chea Kimlay, Phon Kerya, Delfraissy Jean-François, Nerrienet Eric
Primary Institution: Institut Pasteur du Cambodge
Hypothesis
What is the resistance pattern of protease and integrase coding regions in HIV-1 CRF01-AE infected patients failing LPV-based 2nd line regimen in Cambodia?
Conclusion
About 30% of Cambodian patients on LPV/r-based 2nd line regimen developed resistance mutations to multiple protease inhibitors.
Supporting Evidence
- 28 out of 95 patients developed resistance mutations to multiple protease inhibitors.
- Most patients were not naïve to protease inhibitors before starting LPV/r.
- The study highlights the need for evaluating the efficacy of LPV/r-based regimens.
Takeaway
Some people in Cambodia who are taking a specific HIV medicine are not getting better because the virus is changing and becoming resistant to the medicine.
Methodology
Analysis of drug resistance genotyping of 95 HIV-1 strains from patients on LPV/r-based 2nd line regimen.
Limitations
The study may not represent all HIV-1 infected patients in Cambodia due to the specific cohort studied.
Participant Demographics
HIV-1 CRF01-AE infected patients in Cambodia, with a median duration on LPV/r regimen of 34.5 months.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website